Alkermes plc. Deferred Revenue
Alkermes plc. (ALKS) had Deferred Revenue of $1.96 million as of 2017-12-31, per its 10-K filed 2018-02-16.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2018-02-16
- 2017-12-31: Deferred Revenue, Current $1.96M.
- 2017-09-30: Deferred Revenue, Current $1.83M.
- 2017-06-30: Deferred Revenue, Current $1.80M.
- 2017-03-31: Deferred Revenue, Current $2.43M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2017-12-31 | $1.96M 10-K · filed 2018-02-16 |
| 2017-09-30 | $1.83M 10-Q · filed 2017-10-26 |
| 2017-06-30 | $1.80M 10-Q · filed 2017-07-27 |
| 2017-03-31 | $2.43M 10-Q · filed 2017-04-27 |
| 2016-12-31 | $1.94M 10-K · filed 2018-02-16 |
| 2016-09-30 | $1.52M 10-Q · filed 2016-11-02 |
| 2016-06-30 | $1.84M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $1.83M 10-Q · filed 2016-04-28 |
| 2015-12-31 | $1.74M 10-K · filed 2017-02-17 |
| 2015-09-30 | $1.69M 10-Q · filed 2015-10-29 |
| 2015-06-30 | $1.75M 10-Q · filed 2015-07-30 |
| 2015-03-31 | $2.29M 10-Q · filed 2015-04-30 |
| 2014-12-31 | $2.57M 10-K · filed 2016-02-25 |
| 2014-09-30 | $3.06M 10-Q · filed 2014-10-29 |
| 2014-06-30 | $2.38M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $2.26M 10-Q · filed 2014-04-30 |
| 2013-12-31 | $2.97M 10-K · filed 2015-02-24 |
| 2013-09-30 | $2.69M 10-Q · filed 2013-10-31 |
| 2013-06-30 | $2.13M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $2.27M 10-KT · filed 2014-02-27 |
| 2012-12-31 | $2.87M 10-Q · filed 2013-01-31 |
| 2012-09-30 | $3.58M 10-Q · filed 2012-11-01 |
| 2012-06-30 | $10.01M 10-Q · filed 2012-07-26 |
| 2012-03-31 | $6.91M 10-K · filed 2013-05-23 |
| 2011-12-31 | $5.12M 10-Q · filed 2012-02-02 |
| 2011-09-30 | $4.25M 10-Q · filed 2011-11-03 |
| 2011-03-31 | $3.12M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |